STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1164 by analyst upside · 2026-06-27
TYRA
Tyra Biosciences, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+63.0%
implied upside to consensus target
Current Price $31.88
Consensus Target $51.97
Bull Target $59.62
Bear Target $42.0
Analysts Covering 12
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
10
Hold
0
Sell
0
52-Week Low $9.03
52-Week High $40.65
YTD Return +19.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -11.3x
EPS (TTM) $-2.18
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $9.03
52-Week High $40.65
Current Price $31.88
Bear Target $42.0
Bull Target $59.62
● Now $31.88 ● Target $51.97
TRADING DATA
Avg Volume 958K
YTD Return +19.0%
Analyst Count 12
Consensus Buy
Upside to Target +63.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Tyra Biosciences, Inc. (TYRA) is currently trading at $31.88 with a Wall Street consensus price target of $51.97, implying potential upside of 63.0% over the next 12 months. 12 analysts currently cover TYRA, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $59.62, while the most cautious has a target of $42.0.

TYRA operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 19.0% year-to-date and is currently trading near the upper end of its 52-week range of $9.03 – $40.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TYRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jones Trading ● Initiated
Buy 2026-06-17 57% win rate (14 calls)
B of A Securities — Reiterated
Buy → Buy 2026-06-10 Building track record
Wolfe Research ● Initiated
Peer Perform 2026-05-19 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-05-14 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-04-15 62% win rate (8 calls)
Canaccord Genuity ● Initiated
Buy 2026-04-06 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-03-20 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-02-24 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →